

# WEEKLY RESPIRATORY VIRUS SURVEILLANCE



Week 11 - Week Ending Mar 16, 2024

For the week ending Mar 16, 2190 respiratory patient specimens were submitted for Influenza A/B and Respiratory Syncytial Virus (RSV) testing.

Influenza A was detected in 177 of 2190 specimens (8.1%).



Influenza B was detected in 113 of 2190 specimens (5.16%).

RSV was detected in 40 of 2190 specimens (2%).



# WEEKLY RESPIRATORY VIRUS SURVEILLANCE

Week 11 - Week Ending Mar 16, 2024





# WEEKLY RESPIRATORY VIRUS SURVEILLANCE

Week 11 - Week Ending Mar 16, 2024

For the week ending Mar 16, 2485 respiratory patient specimen were submitted for COVID-19 testing.



SARS-CoV-2 was detected in 133 of 2485 specimens (5.4%).



# WEEKLY RESPIRATORY VIRUS SURVEILLANCE

Week 11 - Week Ending Mar 16, 2024

For the week ending Mar 16, 84 respiratory patient specimens were submitted for Human Metapneumovirus (hMPV), Adenovirus (AdV), & Rhinovirus (RV) testing.  
 hMPV was detected in 2 of 84 specimens (2.4%).  
 AdV was detected in 2 of 84 specimens (2.4%).  
 RV was detected in 14 of 84 specimens (16.7%).



# WEEKLY RESPIRATORY VIRUS SURVEILLANCE

Week 11 - Week Ending Mar 16, 2024

For the week ending Mar 16, 75 respiratory patient specimens were submitted for Parainfluenza (PIV) testing.

PIV1 was detected in 2 of 75 specimens (2.7%).  
 PIV2 was detected in 0 of 75 specimens (0%).  
 PIV3 was detected in 2 of 75 specimens (2.7%).  
 PIV4 was detected in 0 of 75 specimens (0%).

